CHO-B7H3

Disclaimer: The prices displayed for cell lines are exclusively for not-for-profit customers. If you represent a commercial entity, please contact us for alternative pricing.

The CHO-B7H3 cell line is a stable recombinant CHO (Chinese Hamster Ovary) cell line engineered to express the B7-H3 receptor at a high level, approximately 430,000 molecules per cell. This cell line was developed using innovative landing pad technology, which ensures precise and reproducible integration of the B7-H3 gene at a specific, pre-validated genomic locus. B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint proteins and is overexpressed in various cancers. It plays a critical role in immune evasion by tumor cells and is associated with poor prognosis in cancer patients. This makes B7-H3 a promising target for cancer immunotherapy, particularly in the development of checkpoint inhibitors and antibody-drug conjugates.
The expression of B7-H3 in this cell line was confirmed using flow cytometry with a target-specific antibody, ensuring reliable and consistent receptor density across the cell population.